These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33143745)

  • 1. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.
    Andlauer TFM; Link J; Martin D; Ryner M; Hermanrud C; Grummel V; Auer M; Hegen H; Aly L; Gasperi C; Knier B; Müller-Myhsok B; Jensen PEH; Sellebjerg F; Kockum I; Olsson T; Pallardy M; Spindeldreher S; Deisenhammer F; Fogdell-Hahn A; Hemmer B;
    BMC Med; 2020 Nov; 18(1):298. PubMed ID: 33143745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
    PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    Bachelet D; Hässler S; Mbogning C; Link J; Ryner M; Ramanujam R; Auer M; Hyldgaard Jensen PE; Koch-Henriksen N; Warnke C; Ingenhoven K; Buck D; Grummel V; Lawton A; Donnellan N; Hincelin-Mery A; Sikkema D; Pallardy M; Kieseier B; Hemmer B; Hartung HP; Soelberg Sorensen P; Deisenhammer F; Dönnes P; Davidson J; Fogdell-Hahn A; Broët P;
    PLoS One; 2016; 11(11):e0162752. PubMed ID: 27806057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
    Hässler S; Bachelet D; Duhaze J; Szely N; Gleizes A; Hacein-Bey Abina S; Aktas O; Auer M; Avouac J; Birchler M; Bouhnik Y; Brocq O; Buck-Martin D; Cadiot G; Carbonnel F; Chowers Y; Comabella M; Derfuss T; De Vries N; Donnellan N; Doukani A; Guger M; Hartung HP; Kubala Havrdova E; Hemmer B; Huizinga T; Ingenhoven K; Hyldgaard-Jensen PE; Jury EC; Khalil M; Kieseier B; Laurén A; Lindberg R; Loercher A; Maggi E; Manson J; Mauri C; Mohand Oumoussa B; Montalban X; Nachury M; Nytrova P; Richez C; Ryner M; Sellebjerg F; Sievers C; Sikkema D; Soubrier M; Tourdot S; Trang C; Vultaggio A; Warnke C; Spindeldreher S; Dönnes P; Hickling TP; Hincelin Mery A; Allez M; Deisenhammer F; Fogdell-Hahn A; Mariette X; Pallardy M; Broët P;
    PLoS Med; 2020 Oct; 17(10):e1003348. PubMed ID: 33125391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ.
    Waddington KE; Papadaki A; Coelewij L; Adriani M; Nytrova P; Kubala Havrdova E; Fogdell-Hahn A; Farrell R; Dönnes P; Pineda-Torra I; Jury EC
    Front Immunol; 2020; 11():1527. PubMed ID: 32765529
    [No Abstract]   [Full Text] [Related]  

  • 7. Human Commensal
    Shahi SK; Jensen SN; Murra AC; Tang N; Guo H; Gibson-Corley KN; Zhang J; Karandikar NJ; Murray JA; Mangalam AK
    Front Immunol; 2020; 11():578648. PubMed ID: 33362764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
    Khan OA; Dhib-Jalbut SS
    Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
    Pachner AR; Warth JD; Pace A; Goelz S;
    Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.
    Sethu S; Govindappa K; Quinn P; Wadhwa M; Stebbings R; Boggild M; Naisbitt D; Kimber I; Pirmohamed M; Park K; Sathish J
    Clin Immunol; 2013 Aug; 148(2):177-85. PubMed ID: 23770627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.
    Deisenhammer F
    CNS Drugs; 2009; 23(5):379-96. PubMed ID: 19453200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.
    Hedström AK; Ryner M; Fink K; Fogdell-Hahn A; Alfredsson L; Olsson T; Hillert J
    Mult Scler; 2014 Apr; 20(4):445-50. PubMed ID: 23924603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients.
    Kalluri SR; Grummel V; Hracsko Z; Pongratz V; Pernpeintner V; Gasperi C; Buck D; Hemmer B;
    J Autoimmun; 2018 Mar; 88():83-90. PubMed ID: 29066027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
    Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.
    Ross C; Clemmesen KM; Svenson M; Sørensen PS; Koch-Henriksen N; Skovgaard GL; Bendtzen K
    Ann Neurol; 2000 Nov; 48(5):706-12. PubMed ID: 11079533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.